Poolbeg Pharma PLC (AIM:POLB) chief executive Jeremy Skillington joins Proactive London's Katie Pilbeam to talk about their deal with testing and support specialist, Eurofins Genomics.
The partnership is to complete the next-generation RNA sequencing of respiratory syncytial virus (RSV) disease progression samples from human viral challenge studies.
The project with Eurofins is expected to be completed by the end of 2021.